Adverse events in deceased hospitalised cancer patients as a measure of quality and safety in end-of-life cancer care.

Anticancer treatment given during the last 30 days of life is associated with a significantly increased rate of adverse events and related mortality. Patients receiving specialist palliative care had significantly fewer adverse events, supporting recommendations of early integration of palliative care in a patient safety perspective.